Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors

• Published in: Investigational new drugs Vol. 28; no. 4; pp. 523 - 528
• Main Authors: Feldman, Darren R., Turkula, Stefan, Ginsberg, Michelle S., Ishill, Nicole, Patil, Sujata, Carousso, Maryann, Bosl, George J., Motzer, Robert J.
• Format: Journal Article
• Language: English
• Published: Boston Springer US 01.08.2010; Springer Nature B.V
• Subjects: Adult; Angiogenesis; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Biomarkers; Biomarkers, Tumor - blood; Cancer therapies; Cells; Chemotherapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug dosages; Drug Resistance, Neoplasm - drug effects; Gene expression; Germination; Humans; Indoles - administration & dosage; Indoles - adverse effects; Kidney cancer; Male; Mediastinal Neoplasms - drug therapy; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Neoplasms, Germ Cell and Embryonal - drug therapy; Neoplasms, Germ Cell and Embryonal - prevention & control; Oncology; Patients; Pharmacology/Toxicology; Phase II Studies; Pyrroles - administration & dosage; Pyrroles - adverse effects; Secondary Prevention; Sunitinib; Testicular Neoplasms - drug therapy; Tumors; Vascular endothelial growth factor; Clinical trial; Sunitinib; Phase II; Germ cell tumors

Summary Vascular endothelial growth factor (VEGF) overexpression and increased angiogenesis have been proposed as having biologic importance in germ cell tumors (GCT). We conducted a single-institution phase II trial of sunitinib, an oral inhibitor of the VEGF receptor, in patients with relapsed or...